Sponsor or institution

Clinical trials and research at Insmed Incorporated

• 7Clinical trials
• 30Countries

Newest trials

All recruiting trials (7)

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• INS1033 Safety and PK Test in Healthy Volunteers

  This study tests how INS1033 behaves in the body and whether it is safe when given to healthy adults.

  Recruiting Phase 1 Insmed Incorporated · Salt Lake City, Utah · NCT07765706

• Treprostinil Palmitil Inhalation Powder: how liver function affects drug in a single-dose test

  This study tests how mild to severe liver impairment changes the amount of treprostinil palmitil and treprostinil in the body after one 80 mcg dose of TPIP in people with and without liver problems.

  Recruiting at 4 sites Phase 1 Insmed Incorporated · Lake Forest, California and 3 other locations · NCT07643155

• Once-daily treprostinil palmitil inhalation powder for PAH

  This study tests whether taking a daily inhaled treprostinil palmitil powder for 24 weeks improves exercise ability in adults with pulmonary arterial hypertension compared to a placebo.

  Recruiting at 39 sites Phase 3 Insmed Incorporated · Los Angeles, California and 38 other locations · NCT07481981

• Single intrathecal injection of INS1202 for adults with ALS (SOD1 or no known mutation)

  This study will try a single injection of INS1202 into the spinal fluid to see if it is safe and how it acts in adults with ALS who have SOD1 mutations or no known ALS gene mutation.

  Recruiting at 9 sites Phase 1 Insmed Incorporated · Phoenix, Arizona and 8 other locations · NCT07290062

• Long-Term TPIP Extension for PH-ILD (open-label)

  This study tests whether long-term use of Treprostinil Palmitil Inhalation Powder helps people with pulmonary hypertension due to interstitial lung disease who completed a prior trial.

  Recruiting at 12 sites Phase 3 Insmed Incorporated · Naples, Florida and 11 other locations · NCT07234032

• Once-daily inhaled treprostinil palmitil for pulmonary hypertension linked to interstitial lung disease

  This trial will test whether once-daily inhaled treprostinil palmitil improves exercise ability over 24 weeks in adults with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 166 sites Phase 3 Insmed Incorporated · Phoenix, Arizona and 185 other locations · NCT07179380

Quick answers

How many clinical trials run by Insmed Incorporated are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 30 countries. The most sites are in United States (7 trials), Japan (3 trials), South Korea (3 trials), Czechia (2 trials), France (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 4, Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →